Table 3.

Comparison of Adverse events for Docetaxel based regimens

	Doc.\Pred. TAX-327 Tannock et al.2	Doc.\EMP\Pred. SWOG 9906 Petrylak et al.3	Doc\EMP\Pred.\Bev CALGB 90006 Picus et al.
Adverse Events Grade 3,4 or 5
Neutropenia	32%	12.5%	69%
Febrile neutropenia	3%	5%	4%
Infection	-	13.6%	16%
Fatigue	5%	-	25%
Pain	-	11%	14%
Thrombosis\Embolism	-	6%	9%
Hemorrhage	-	4%	1%
Death, treatment related	0.3%	2.4%	3.8%
Clinical Outcomes
50% PSA Decline	32%	12.5%	75%
CR\PR –measurable disease	12%	17%	59%
Progression Free Survival	~8.2 months	6.3 months	8.0 months
Overall Survival	19.2 months	17.5 months	24 months